Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.

DuSell CD, Nelson ER, Wang X, Abdo J, Mödder UI, Umetani M, Gesty-Palmer D, Javitt NB, Khosla S, McDonnell DP.

Endocrinology. 2010 Aug;151(8):3675-85. doi: 10.1210/en.2010-0080. Epub 2010 May 25.

2.

27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

He S, Nelson ER.

Maturitas. 2017 Oct;104:29-35. doi: 10.1016/j.maturitas.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
28923174
3.

Re-adopting classical nuclear receptors by cholesterol metabolites.

Umetani M.

J Steroid Biochem Mol Biol. 2016 Mar;157:20-6. doi: 10.1016/j.jsbmb.2015.11.002. Epub 2015 Nov 10. Review.

4.

[Effects of SERMs on bone health. Mechanisms of bone mass control by selective estrogen receptor modulator].

Imai Y, Kato S.

Clin Calcium. 2010 Mar;20(3):339-44. doi: CliCa1003339344. Review. Japanese.

PMID:
20190363
5.

27-Hydroxycholesterol: the first identified endogenous SERM.

Umetani M, Shaul PW.

Trends Endocrinol Metab. 2011 Apr;22(4):130-5. doi: 10.1016/j.tem.2011.01.003. Epub 2011 Feb 23. Review.

6.

The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.

Lee WL, Cheng MH, Tarng DC, Yang WC, Lee FK, Wang PH.

J Chin Med Assoc. 2013 Jul;76(7):365-71. doi: 10.1016/j.jcma.2013.03.010. Epub 2013 May 9. Review.

7.
8.

Androgens: basic biology and clinical implication.

Orwoll ES.

Calcif Tissue Int. 2001 Oct;69(4):185-8. Review.

PMID:
11730246
9.

[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].

Kobayashi H, Hamaya E.

Nihon Yakurigaku Zasshi. 2005 Jan;125(1):37-48. Review. Japanese. No abstract available.

PMID:
15738620
10.

[Melatonin and bone status].

Ostrowska Z, Wołkowska-Pokrywa K, Kos-Kudła B, Swietochowska E, Marek B, Kajdaniuk D.

Pol Merkur Lekarski. 2006 Oct;21(124):389-93. Review. Polish.

PMID:
17205785
11.

Nutritional factors and bone homeostasis: synergistic effect with zinc and genistein in osteogenesis.

Yamaguchi M.

Mol Cell Biochem. 2012 Jul;366(1-2):201-21. doi: 10.1007/s11010-012-1298-7. Epub 2012 Apr 5. Review.

PMID:
22476903
12.

[Regulation of bone metabolisms by estrogen/estrogen receptors signaling].

Imai Y.

Clin Calcium. 2013 Nov;23(11):1621-6. doi: CliCa131116211626. Review. Japanese.

PMID:
24162602
13.

Sex steroids and bone.

Compston JE.

Physiol Rev. 2001 Jan;81(1):419-447. Review.

14.

Skeletal effects of selective oestrogen receptor modulators (SERMs).

Díez JL.

Hum Reprod Update. 2000 May-Jun;6(3):255-8. Review.

PMID:
10874570
15.

Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.

Kangas L, Unkila M.

Steroids. 2013 Dec 11;78(12-13):1273-80. doi: 10.1016/j.steroids.2013.09.003. Epub 2013 Sep 18. Review.

PMID:
24055829
16.

An estrogen receptor basis for raloxifene action in bone.

Bryant HU, Glasebrook AL, Yang NN, Sato M.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):37-44. Review.

PMID:
10418979
17.

Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.

Suzuki A, Sekiguchi S, Asano S, Itoh M.

J Pharmacol Sci. 2008 Apr;106(4):530-5. Review.

18.
19.

Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.

Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P.

Endocr Regul. 2003 Dec;37(4):225-38. Review.

PMID:
15106819
20.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Maeda T, Ke HZ, Simmons H, Thompson D.

Clin Calcium. 2004 Oct;14(10):85-93. Review. Japanese.

PMID:
15577137

Supplemental Content

Support Center